AstraZeneca’s Enhertu Slashes Breast Cancer Recurrence Risk in Landmark Trial

ESMO 2025: 4 Advances in Breast Cancer Shaping Treatment Approaches

Open the article to view the coverage from komen.org

Adjuvant T-DXd Cuts Recurrence Risk in Early Breast Cancer

(MedPage Today) — Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast cancer, according to results… Source link : https://www.medpagetoday.com/meetingcoverage/esmovideopearls/118303 Author : Publish date : 2025-11-04 17:07:00 Copyright for syndicated content belongs to the linked Source. The post Adjuvan…

AstraZeneca’s Enhertu Slashes Breast Cancer Recurrence Risk in Landmark Trial

WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported breakthrough results from the Phase III DESTINY-Breast05 trial, showing that their drug ENHERTU (fam-trastuzumab deruxtecan-nxki) cut the risk of disease recurrence or death by 53% compared with the current standard therapy, T-DM1, in patients with high-risk HER2-positive early breast cancer following neoadjuvant treatment. The findings, unveiled during the European Society for Medical Onc…